Holocene Advisors
DNLI icon

Holocene Advisors’s Denali Therapeutics DNLI Stock Holding History

Holocene Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61.4M Buy
3,195,429
+42,695
+1% +$850K 0.15% 161
2025
Q4 		$52.1M Buy
3,152,734
+17,022
+0.5% +$287K 0.11% 203
2025
Q3 		$45.5M Buy
3,135,712
+2,732,540
+678% +$39.3M 0.1% 192
2025
Q2 		$5.64M Buy
+403,172
New +$5.67M 0.01% 356
2025
Q1 		– Sell
-199,072
Closed -$4.06M – 775
2024
Q4 		$4.06M Buy
199,072
+101,625
+104% +$2.6M 0.01% 430
2024
Q3 		$2.84M Buy
97,447
+38,405
+65% +$952K 0.01% 486
2024
Q2 		$1.37M Sell
59,042
-801,906
-93% -$15.4M 0.01% 578
2024
Q1 		$17.7M Buy
+860,948
New +$16.2M 0.06% 223

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Holocene Advisors's DNLI Position: Q1 2026 in Review

Holocene Advisors increased its Denali Therapeutics (DNLI) stake by 1.4% in Q1 2026, buying an estimated $850K and bringing the position to 3,195,429 shares worth $61.4M. The position accounts for 0.15% of the portfolio, ranked #161.

Holocene Advisors first reported a position in DNLI in Q1 2024 and has held it in 8 quarters since. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Holocene Advisors held 3,195,429 shares of Denali Therapeutics worth $61.4M as of Q1 2026.
  • Holocene Advisors bought 42,695 Denali Therapeutics shares in Q1 2026, an estimated $850K.
  • Denali Therapeutics made up 0.15% of Holocene Advisors's portfolio in Q1 2026, its #161 holding.
  • Holocene Advisors first reported a position in Denali Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • 268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Holocene Advisors's 13F filing for Q1 2026, filed 15 May 2026.